Telix Pharmaceuticals Ltd
Illuccix
prostate cancer imaging
Resolved
197days ago
Phase 3 readout · Dec 22, 2025
What's at stake
Phase 3 trial results for Illuccix in prostate cancer imaging are due Dec 22, 2025. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 11h ago
“Telix ASX disclosure 22 December 2025.”